BioMarin Pharmaceutical (NASDAQ: BMRN) wins FDA approval for $700,000 Batten disease drug Brineura - San Francisco Business Times
Jennifer Bienaime with Jean-Jacques Bienaime
BioMarin Pharmaceutical 1Q loss rises amid higher expenses for product launch
Jean-Jacques Bienaime Net Worth (2022) | wallmine
BioMarin Pharmaceutical Inc - Jean-Jacques Bienaimé Chairman and Chief Executive Officer
On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime
Jean-Jacques Bienaime with Jennifer Kano
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
BioMarin (NASDAQ: BMRN) sues to stop Dr. Reddy's (NYSE: RDY) from selling generic version of PKU drug Kuvan - San Francisco Business Times
Jean-Jacques Bienaime
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
Chairman and CEO of BioMarin, Jean-Jacques Bienaime is photographed... News Photo - Getty Images
People | Nature Biotechnology
Jan-Jacques Bienaime with Lana Bondar
3.5: Testimony from Jean-Jacques Bienaimé (CEO - BioMarin Pharmaceutical) - Unit 3: Investing in Europe | Coursera
Jean-Jacques Bienaime - Crunchbase Person Profile
Rare Diseases | LOTUS EDITIONS
Jean Jacques Bienaime – North Bay Leadership Council
BioMarin Pharmaceutical shares rise after possible takeover from Roche
J.P. Morgan Healthcare Conference
Jean-Jacques Bienaimé - Chairman & CEO at BioMarin Pharmaceutical | The Org
Jean Jacques Bienaime Sells 1,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock - Opera News
Jean-Jacques Bienaimé BioMarin | The CEO Magazine
Jean Jacques Bienaime vs Heather Bresch | Comparably
BioMarin's CEO On Its Product Pipeline
